Notably, dual GLP-1 agonist/GIP agonist and GLP-1 agonist/GIP antagonists have both been shown to enhance glucose tolerance and β cell function in individuals with T2D, highlighting the need for further investigation into their specific mechanisms of action. Here, GIP is linked to type 2 diabetes mellitus.